CYNATA THERAPEUTICS LTD

0.011

0.000

Volume:- -

Turnover:- -

Market Cap:2.68M

PE:-0.29

High:0.011

Open:0.011

Low:0.011

Close:0.011

52wk High:0.435

52wk Low:0.011

Shares:243.45M

Float Shares:175.62M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.038

EPS(LYR):-0.038

ROE:-325.34%

ROA:-113.06%

PB:-6.79

PE(LYR):-0.29

Loading ...

Overview Company News Filings

Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period

MT Newswires Live

·

Mar 30

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live

·

Mar 09

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.etasphere.com/stock/CYP.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","market":"AU","secType":"STK","nameCN":"CYNATA THERAPEUTICS LTD","latestPrice":0.011,"timestamp":1788402220463,"preClose":0.011,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"CYNATA THERAPEUTICS LTD","floatShares":175624818,"shares":243454369,"eps":-0.0384,"marketStatus":"Trading","change":0,"latestTime":"09-03 12:33:32 AEST","open":0.011,"high":0.011,"low":0.011,"amount":0,"amplitude":0,"askPrice":0.012,"askSize":865855,"bidPrice":0.011,"bidSize":483840,"shortable":3,"etf":0,"ttmEps":-0.0384,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788415200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.011,"openAndCloseTimeList":[[1788393600000,1788415200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CYP.AU","preClose":0.011,"auctionPrice":0.011,"auctionVolume":65946,"auction":3,"marketStatus":"盘后竞价","timestamp":1788328833440}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","floatShares":175624818,"roa":"-113.06%","roe":"-325.34%","lyrEps":-0.0384,"shares":243454369,"dividePrice":0,"high":0.011,"amplitude":0,"preClose":0.011,"low":0.011,"week52Low":0.011,"pbRate":"-6.79","psRate":"1.50","week52High":0.435,"institutionHeld":0,"latestPrice":0.011,"committee":-0.283038,"eps":-0.0384,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.0384,"open":0.011,"prevYearClose":0.345,"prevWeekClose":0.011,"prevMonthClose":0.011,"prevQuarterClose":0.014,"fiveDayClose":0.011,"twentyDayClose":0.013,"sixtyDayClose":0.26,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-12-15","symbol":"CYP.AU","defaultRemindTime":1607986800000,"type":"split","dateTimestamp":1607950800000,"forFactor":2147483647,"toFactor":2147483647,"ratio":0.997023}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYP.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623927367","title":"Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2623927367","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623927367?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:48","pubTimestamp":1774838890,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said the 100-day primary evaluation period was completed for the final participant enrolled in its phase two clinical trial of its CYP-001 drug candidate in adults with acute graft versus host disease, according to a Monday Australian bourse filing.A total of 65 participants were enrolled in the trial, and the participants were randomized to receive either steroids plus CYP-001 or steroids plus placebo.The primary endpoint is the overall response rate at day 28, and results are anticipated in June.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LENZ","BK4139","CYP.AU","BK7501","BK4539","BK7067","BK4218","HST","BK7508","BK4585","BK4007","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK7501","BK4139","MSB.AU","BK7508","MESO","BK4007","BK7067","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":22,"code":"91000000","status":"200"}]}}